Shares of Sunshine Heart Inc (NASDAQ:CHFS) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.
Analysts have set a one year consensus price objective of $15.00 for the company, according to Zacks. Zacks has also given Sunshine Heart an industry rank of 166 out of 265 based on the ratings given to its competitors.
Several research firms recently issued reports on CHFS. ValuEngine upgraded shares of Sunshine Heart from a “strong sell” rating to a “sell” rating in a research report on Tuesday, October 31st. Zacks Investment Research upgraded shares of Sunshine Heart from a “hold” rating to a “buy” rating and set a $4.00 price target on the stock in a research report on Monday, January 8th.
Sunshine Heart Company Profile
CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sunshine Heart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart and related companies with MarketBeat.com's FREE daily email newsletter.